Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Marina Cavazzana(Université Rennes 2), Alain Fischer(Inserm), Éric Yvon(Shanghai Cell Therapy Research Institute), Philippe Bousso(Inserm), Salima Hacein‐Bey(Inserm), Geneviève de Saint Basile(Inserm), Jean‐Laurent Casanova(Howard Hughes Medical Institute), Patrick Nusbaum(Gene Therapy Laboratory), Fabian Gross(Centre National de la Recherche Scientifique), Stéphanie Certain(Inserm), Françoise Le Deist(Centre National de la Recherche Scientifique), Françoise Selz(Inserm), Christophe Hue(Inserm)
Cited by 2,619
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k